OR WAIT null SECS
On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.
March 28, 2024
Article
At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline.
March 27, 2024
The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.
These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.
Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab.
March 26, 2024
Compared with RA, patients with PsA had a higher diagnostic delay and a greater time between the onset of symptoms and the start of treatment.
Psoriatic arthritis and spondyloarthritis occurred earlier in children and adolescents with IBD than in the matched references without IBD.
March 25, 2024
These data suggest risankizumab was both safe and efficacious through 100 weeks for PsA patients, with no new safety signals.
These data from the DISCOVER-2 study highlight improvements in patient-reported outcomes for patients who are biologic-naïve and have PsA.
March 22, 2024
This analysis indicates that a combined, 22-week Mediterranean and ketogenic diet for patients with psoriatic disease led to beneficial results.
March 21, 2024
These data highlight the potential window of opportunity for PsA patients’ diagnoses and any patient characteristics of those with longer diagnostic delays.